Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.110
+0.050 (4.72%)
At close: Aug 13, 2025, 4:00 PM
1.110
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:19 AM EDT
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $28.87M in the quarter ending June 30, 2025, with 1,652.64% growth. This brings the company's revenue in the last twelve months to $58.43M, up 1,504.83% year-over-year. In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth.
Revenue (ttm)
$58.43M
Revenue Growth
+1,504.83%
P/S Ratio
6.88
Revenue / Employee
$567,301
Employees
103
Market Cap
403.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LXRX News
- 7 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 14 days ago - Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 22 days ago - Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 27 days ago - Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - GlobeNewsWire
- 7 weeks ago - Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) - GlobeNewsWire
- 2 months ago - Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - GlobeNewsWire
- 2 months ago - Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire